Patents Examined by Christina M Borgeest
-
Patent number: 11965879Abstract: A method of detecting the expression level of miRNA markers in a biological sample obtained from a mammal is provided. The method incudes the steps of i) detecting the expression level of one or more miRNA markers selected from the group of miR-199a-3p, miR-143-3p, miR-340-5p, let-7b-5p, miR-21-5p, miR-17-5p, miR-20a-5p and miR-103a-3p, in the biological sample; ii) detecting the expression level of at least one miRNA reference marker selected from miR-148b-3p and miR-30e-5p in the biological sample; and iii) normalizing the expression level of the miRNA marker(s) against the expression level of the miRNA reference marker in the sample and in a control. The method is useful for the diagnosis of endometriosis, monitoring of patient response to treatment, and assessment of disease progression and/or severity.Type: GrantFiled: August 21, 2020Date of Patent: April 23, 2024Assignee: McMaster UniversityInventor: Warren G Foster
-
Patent number: 11919964Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.Type: GrantFiled: August 27, 2020Date of Patent: March 5, 2024Assignee: AMGEN INC.Inventors: Gunasekaran Kannan, Ling Liu, Edward J. Belouski, Cen Xu
-
Patent number: 11912750Abstract: The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.Type: GrantFiled: November 9, 2017Date of Patent: February 27, 2024Assignee: Keros Therapeutics, Inc.Inventors: Jasbir S. Seehra, Jennifer Lachey
-
Patent number: 11890322Abstract: The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages.Type: GrantFiled: July 13, 2021Date of Patent: February 6, 2024Assignee: The Jackson LaboratoryInventors: Robert E. Braun, Manju Sharma
-
Patent number: 11883438Abstract: It is an object to provide a technique useful for embryo transfer and development of reproductive medical care. Provided are a sperm activator containing a disrupted product of one or more cells selected from the group consisting of adipose tissue-derived stem cells, dental pulp-derived stem cells, bone marrow-derived stem cells, and umbilical cord blood-derived stem cells as an active ingredient, and an artificial insemination method utilizing the same.Type: GrantFiled: August 23, 2017Date of Patent: January 30, 2024Assignees: National University Corporation Nagoya University, Gifu University, Gifu PrefectureInventors: Tokunori Yamamoto, Satoshi Suzuki, Yasuhito Funahashi, Yoshihisa Matsukawa, Momokazu Gotoh, Tomohiro Kitayama, Yoichiro Hoshino, Tetsuma Murase
-
Patent number: 11883473Abstract: A method for treating dyslexia or reading developmental disorder (RDD) in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient. In infants or toddlers—from about birth to 5 years old, botulinum toxin is used to prevent or minimize damage to the developing brain that would result in dyslexia; in older children and adult patients with dyslexia, botulinum toxin will be used to reduce or eliminate their symptoms.Type: GrantFiled: March 17, 2021Date of Patent: January 30, 2024Assignee: PENLAND FOUNDATIONInventor: Roland M. Williams
-
Patent number: 11878997Abstract: This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.Type: GrantFiled: June 30, 2021Date of Patent: January 23, 2024Assignees: Burke Neurological Institute, University of Vermont and State Agricultural CollegeInventors: Rajiv R. Ratan, Ishraq Alim, Saravanan Karuppagounder, Robert Hondal
-
Patent number: 11865122Abstract: Provided are methods for slowing, halting, and reversing gray matter atrophy and progression of disability in certain neurodegenerative diseases, including multiple sclerosis, using estrogen, alone or in combination with another agent.Type: GrantFiled: October 28, 2020Date of Patent: January 9, 2024Assignee: The Regents of the University of CaliforniaInventor: Rhonda R. Voskuhl
-
Patent number: 11866501Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: August 26, 2020Date of Patent: January 9, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Katharina Florin, Cynthia Hess Kenny, Sarah Kathleen Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir H. Voynov, Haiguang Xiao
-
Patent number: 11820833Abstract: An isolated peptide of up to 6 amino acids comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR is disclosed. Also disclosed is an isolated peptide comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR, wherein the peptide comprises a modification in at least one amino acid. Also disclosed is a molecule comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR attached to a heterologous moiety. Pharmaceutical compositions and methods of treatment are also disclosed.Type: GrantFiled: June 2, 2017Date of Patent: November 21, 2023Assignee: Tel HaShomer Medical Research infrastructure and Services Ltd.Inventors: Nicola Maggio, Joab Chapman, Efrat Shavit Stein
-
Patent number: 11820816Abstract: The present invention relates to anti-VEGF antibodies and methods of their production and their use.Type: GrantFiled: June 26, 2020Date of Patent: November 21, 2023Assignee: Hoffman-La Roche Inc.Inventors: Stefan Dengl, Sebastian Fenn, Guy Georges, Joerg Moelleken, Francesca Ros, Esther Koenigsberger
-
Patent number: 11774441Abstract: The present invention relates to a method for determining the fertility of spermatozoa, said method comprising determining the total content of Vimentin variant 3 (Vim3) per spermatozoon and/or the spatial localization of the Vim3 in the spermatozoa, wherein a decreased amount of total content and/or decreased amount of (or even missing) accumulation of Vim3 in the mid piece of the spermatozoa indicates decreased fertility. Further, the present invention refers to a dipstick usable for this method. Moreover, the present invention relates to further methods and uses in the context of the present invention.Type: GrantFiled: April 6, 2018Date of Patent: October 3, 2023Assignee: Universität zu KölnInventors: Melanie von Brandenstein, Ali Tok
-
Patent number: 11752193Abstract: The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects.Type: GrantFiled: October 2, 2020Date of Patent: September 12, 2023Assignee: University of Vermont and State Agricultural CollegeInventors: Mercedes Rincon, Ketki M. Hatle
-
Patent number: 11744881Abstract: A method for treating Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient. The administration of the botulinum toxin prevents an overproduction of glutamate, Substance P, and CGRP in a sensory system and thereby inhibits a migration of the glutamate, Substance P, and CGRP to the motor system, which otherwise would cause neuroexcitatory toxicity that results in the death of motor neurons.Type: GrantFiled: March 29, 2021Date of Patent: September 5, 2023Assignee: PENLAND FOUNDATIONInventor: Roland M. Williams
-
Patent number: 11744879Abstract: Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility in patients having high AMH and low bodyweight.Type: GrantFiled: August 31, 2018Date of Patent: September 5, 2023Assignee: FERRING B.V.Inventors: Joan-Carles Arce Saez, Lisbeth Helmgaard, Bjarke Mirner Klein
-
Patent number: 11690897Abstract: This invention relates to methods of using salt inducible kinase inhibitors to enhance female fertility.Type: GrantFiled: February 4, 2020Date of Patent: July 4, 2023Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: Carlos Stocco
-
Patent number: 11674184Abstract: The present invention relates to a biomarker composition for diagnosing radiation-resistant cancer comprising PMVK as an active ingredient and a method of diagnosing radiation-resistant cancer using the same, and when the PMVK is knocked down, it is confirmed that the survival rate of cancer cells decreases during radiation treatment, and based on this, the possibility as a factor related to radiation therapy resistance to cancer was suggested, and the PMVK can be used as a new target to enhance the effect of radiation therapy on human cancer cells.Type: GrantFiled: November 21, 2018Date of Patent: June 13, 2023Assignee: ENHANCEDBIO INC.Inventors: Eun Kyung Choi, Seong-Yun Jeong, Si Yeol Song, Yun-Yong Park, Seok Soon Park, Eun Jin Ju, Eun Jung Ko
-
Patent number: 11666635Abstract: The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.Type: GrantFiled: September 14, 2020Date of Patent: June 6, 2023Assignee: Ferring B.V.Inventors: Helen Ulrika Sjögren, Charlotte Hojer-Pedersen
-
Patent number: 11654181Abstract: This invention relates to C-X-C motif chemokine 12 (CXCL12), also known as stromal cell-derived factor 1 (SDF-1), vectors encoding the same, and methods of using the same for a male subject that has undergone prostate surgery to treat urological symptoms of the surgery.Type: GrantFiled: August 10, 2018Date of Patent: May 23, 2023Assignee: Wake Forest University Health SciencesInventor: James K. Williams
-
Patent number: 11638740Abstract: Further according to the present disclosure, there are methods for promoting egg maturation in assisted reproductive technologies, such as in in vitro fertilization (IVF) or in an embryo transfer (ET) process. There are also methods for decreasing the rate of ovarian hyperstimulation syndrome (OHSS), providing comparable or improved pregnancy rates, decreasing the time to pregnancy, and inhibiting premature ovulation. The methods include the step of administering a therapeutically effective amount of an active pharmaceutical ingredient of 2-(N-acetyl-D-tyrosyl-trans-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl) hydrazinocarbonyl-L-leucyl-N?-methyl-L-arginyl-L-tryptophanamide or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 23, 2021Date of Patent: May 2, 2023Assignee: Myovant Sciences GmbHInventors: Vijaykumar Reddy Rajasekhar, Brendan Mark Johnson, Laura Ann Williams